Page 21 - Replimune Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

In this piece, we will take a look at the ten best stocks to buy under $20 according to Jeremy Green's Redmile Group.

Inhibrx (NASDAQ:INBX – Get Rating) and Replimune Group (NASDAQ:REPL – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings. Earnings & Valuation This table compares Inhibrx and Replimune Group’s […]

Replimune Group (NASDAQ:REPL – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s […]

Replimune Group (NASDAQ:REPL – Get Rating) had its price target dropped by equities researchers at JPMorgan Chase & Co. from $47.00 to $39.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 98.27% […]

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have earned a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target […]